IMVIF

0.0001--
MK

Michael Kalos

Member of Scientific Advisory Board

Dr. Michael Kalos, Ph.D., is Member of Scientific Advisory Board of Shennon Biotechnologies Inc. from 2026. Dr. Kalos is Member of Scientific Advisory Council of Cancer Research Institute, Inc. He is Scientific Advisor of Modi Ventures Capital Management LLC from 2026. He is Member of Scientific Advisory Board of Anocca AB. He serves as Scientific Advisor of cTRL Therapeutics USA, Inc. He is Member of Scientific Advisory Board of Vittoria Biotherapeutics, Inc. Dr. Kalos is Member of Development Advisory Panel of Revitope Oncology, Inc. Dr. Kalos serves as an Independent Director at IMV Inc. since May 2021. He served as Director at IMV Inc. since May 11, 2021. Dr. Kalos is an internationally recognized expert in T cell therapy and immunotherapy and has experience and expertise in cell therapy, oncology vaccines and immunooncology. Most recently he served as an Executive Vice President and Head of R&D at ArsenalBio since 2019 until 2020. At ArsenalBio, he led the development of the research and development and product development strategy for the company’s first product. Prior to ArsenalBio he served as Vice President of Immuno-oncology and Oncology Cell Therapies at Janssen, since 2018 until 2019, where he led corporate internal and external strategy and efforts in cell therapy, neoantigen vaccines and immuno-oncology. Prior to Janssen, he served as the Chief Scientific Officer of Cancer Immunobiology and immuno-oncology at Eli Lilly and Company since 2013 until 2018, where he established and led internal and external corporate strategy in immuno-oncology, including biologics, bi-specifics, vaccines and cell therapy. Prior to joining the biopharmaceutical sector, he had been in academia, where he focused on the development of integrated translational biomarker programs to support the development of cell therapy and immunotherapy programs. The laboratory he founded and directed at the University of Pennsylvania played a key role in the success of the cell therapy program at the University of Pennsylvania, including clinical development of the CTL019 program that was licensed to Novartis and led to the approval of Kymriah. Dr. Kalos has co-authored over 85 peer-reviewed manuscripts, including multiple highly cited articles in high-impact journals that have helped define the space of CAR- and TCR- based T cell therapy, as well as book chapters in the field of cancer immunotherapy and has 26 issued patents in the field of cell therapy, immunotherapy and vaccines. He actively serves and has served as an advisory member for international immunotherapy consortia and societies as well as biopharmaceutical companies. Michael frequently speaks at national and international scientific meetings and is dedicated to advancing immunotherapy and biomarkers, focusing on improving the development and evaluation of early-stage immunotherapy protocols. He serves as a Member of Scientific Advisory Board at Lykan BioScience, LLC from September, 2022. He serves as a Member of Scientific Advisory Board of Roslinct since August, 2022. He is Senior Venture Partner and Head of Cell Therapy at Orange Grove Bio LLC since 2022. He was Director at CTRL Therapeutics USA, Inc. He serves as a Managing Director and Advisor at Next Pillar Consulting, LLC since 2020. Dr. Kalos was Senior Advisory Board Member at Orange Grove Bio LLC until 2022. He serves as a Scientific Advisory Board Member at Senti Biosciences Holdings, Inc. since August 2021. He serves as Member of Scientific and Clinical Advisory Board at Cue Biopharma, Inc. since February 2021. He serves as Member of Scientific Advisory Board at Adicet Bio, Inc. since July 2021. He served as Member of Scientific Advisory Board at Immunai Inc. from 2022 to July 2022. Dr. Kalos obtained his Ph.D. from the University of Minnesota and completed post-doctoral training in the laboratory of Phil Greenberg at the Fred Hutchinson Cancer Research Center.

Positions